News
thumbnail
Deal MakingSandoz picks up Coherus’ Lucentis for $170mSandoz picks up Coherus’ Lucentis for $170m
In an effort to focus on oncology, Coherus BioSciences has offloaded its Lucentis biosimilar Cimerli (ranibizumab) to Sandoz.
In an effort to focus on oncology, Coherus BioSciences has offloaded its Lucentis biosimilar Cimerli (ranibizumab) to Sandoz.